The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na v 1.7 channel blocker
PF-06456384 is an extremely potent and selective blocker of the Na 1.7 sodium channel designed as a potential intravenous (i.v.) analgesic targeting high potency and rapid clearance to minimize the potential for residual effects following the end of infusion. In our previous experience targeting ora...
Gespeichert in:
Veröffentlicht in: | Biopharmaceutics & drug disposition 2018-09, Vol.39 (8), p.388-393 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 393 |
---|---|
container_issue | 8 |
container_start_page | 388 |
container_title | Biopharmaceutics & drug disposition |
container_volume | 39 |
creator | Pike, Andy Flanagan, Neil J Storer, R Ian Swain, Nigel A Tseng, Elaine |
description | PF-06456384 is an extremely potent and selective blocker of the Na
1.7 sodium channel designed as a potential intravenous (i.v.) analgesic targeting high potency and rapid clearance to minimize the potential for residual effects following the end of infusion. In our previous experience targeting oral molecules, the requirement to obtain potent, Na
1.7 selective molecules led to a focus on acidic, amphipilic compounds cleared primarily by organic anion-transporting polypeptide mediated hepatic uptake and subsequent biliary excretion. However, the physicochemical properties of the i.v. lead matter were substantially different, moving from acidic, amphiphilic chemical space to zwitterions as well as substantially increasing molecular weight. This report describes the continued relevance of organic anion-transporting polypeptide driven hepatic uptake in this physicochemical space and highlights an apparent impact of the formulation excipient Solutol on the clearance and distribution of PF-06456384. |
doi_str_mv | 10.1002/bdd.2156 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_bdd_2156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30175851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561-183a63a15a370ba1a39093895e226564ae5ad93ac9d9f686362710433d6577923</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqUg8QXISzYpHrt24iWqeEkVbLpgF01spw2kduSklfgE_hq3BTYz0twzd3EIuQY2Bcb4XWXtlINUJ2QMTOuMFfB-SsYMZjzjecFH5KLvPxhjCgDOyUgwyGUhYUy-l2tHY2gdDTUNcYW-MTSN4LMhou-7EIfGr2gX2q_OdUNjXZ9yS-sQN9sWh0TSxtMh1ZjWYfox7gDYph9iU20PRCpH6sPOtfQV6Y7CNKdmjd6nQ9UG8-niJTmrse3d1e-ekOXjw3L-nC3enl7m94vMSAUZFAKVQJAoclYhoNBMi0JLx7mSaoZOotUCjba6VoUSiufAZkJYJfNcczEht8daE0PfR1eXXWw2GL9KYOVeZplklnuZCb05ot222jj7D_7ZEz-bq2_L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na v 1.7 channel blocker</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Pike, Andy ; Flanagan, Neil J ; Storer, R Ian ; Swain, Nigel A ; Tseng, Elaine</creator><creatorcontrib>Pike, Andy ; Flanagan, Neil J ; Storer, R Ian ; Swain, Nigel A ; Tseng, Elaine</creatorcontrib><description>PF-06456384 is an extremely potent and selective blocker of the Na
1.7 sodium channel designed as a potential intravenous (i.v.) analgesic targeting high potency and rapid clearance to minimize the potential for residual effects following the end of infusion. In our previous experience targeting oral molecules, the requirement to obtain potent, Na
1.7 selective molecules led to a focus on acidic, amphipilic compounds cleared primarily by organic anion-transporting polypeptide mediated hepatic uptake and subsequent biliary excretion. However, the physicochemical properties of the i.v. lead matter were substantially different, moving from acidic, amphiphilic chemical space to zwitterions as well as substantially increasing molecular weight. This report describes the continued relevance of organic anion-transporting polypeptide driven hepatic uptake in this physicochemical space and highlights an apparent impact of the formulation excipient Solutol on the clearance and distribution of PF-06456384.</description><identifier>ISSN: 0142-2782</identifier><identifier>EISSN: 1099-081X</identifier><identifier>DOI: 10.1002/bdd.2156</identifier><identifier>PMID: 30175851</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Drug Interactions ; Excipients - pharmacokinetics ; Male ; NAV1.7 Voltage-Gated Sodium Channel ; Organic Anion Transporters - metabolism ; Piperidines - pharmacokinetics ; Polyethylene Glycols - pharmacokinetics ; Pyridines - pharmacokinetics ; Rats, Wistar ; Stearic Acids - pharmacokinetics ; Thiadiazoles - pharmacokinetics ; Voltage-Gated Sodium Channel Blockers - pharmacokinetics</subject><ispartof>Biopharmaceutics & drug disposition, 2018-09, Vol.39 (8), p.388-393</ispartof><rights>2018 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c561-183a63a15a370ba1a39093895e226564ae5ad93ac9d9f686362710433d6577923</cites><orcidid>0000-0001-9053-9664</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30175851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pike, Andy</creatorcontrib><creatorcontrib>Flanagan, Neil J</creatorcontrib><creatorcontrib>Storer, R Ian</creatorcontrib><creatorcontrib>Swain, Nigel A</creatorcontrib><creatorcontrib>Tseng, Elaine</creatorcontrib><title>The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na v 1.7 channel blocker</title><title>Biopharmaceutics & drug disposition</title><addtitle>Biopharm Drug Dispos</addtitle><description>PF-06456384 is an extremely potent and selective blocker of the Na
1.7 sodium channel designed as a potential intravenous (i.v.) analgesic targeting high potency and rapid clearance to minimize the potential for residual effects following the end of infusion. In our previous experience targeting oral molecules, the requirement to obtain potent, Na
1.7 selective molecules led to a focus on acidic, amphipilic compounds cleared primarily by organic anion-transporting polypeptide mediated hepatic uptake and subsequent biliary excretion. However, the physicochemical properties of the i.v. lead matter were substantially different, moving from acidic, amphiphilic chemical space to zwitterions as well as substantially increasing molecular weight. This report describes the continued relevance of organic anion-transporting polypeptide driven hepatic uptake in this physicochemical space and highlights an apparent impact of the formulation excipient Solutol on the clearance and distribution of PF-06456384.</description><subject>Animals</subject><subject>Drug Interactions</subject><subject>Excipients - pharmacokinetics</subject><subject>Male</subject><subject>NAV1.7 Voltage-Gated Sodium Channel</subject><subject>Organic Anion Transporters - metabolism</subject><subject>Piperidines - pharmacokinetics</subject><subject>Polyethylene Glycols - pharmacokinetics</subject><subject>Pyridines - pharmacokinetics</subject><subject>Rats, Wistar</subject><subject>Stearic Acids - pharmacokinetics</subject><subject>Thiadiazoles - pharmacokinetics</subject><subject>Voltage-Gated Sodium Channel Blockers - pharmacokinetics</subject><issn>0142-2782</issn><issn>1099-081X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0EoqUg8QXISzYpHrt24iWqeEkVbLpgF01spw2kduSklfgE_hq3BTYz0twzd3EIuQY2Bcb4XWXtlINUJ2QMTOuMFfB-SsYMZjzjecFH5KLvPxhjCgDOyUgwyGUhYUy-l2tHY2gdDTUNcYW-MTSN4LMhou-7EIfGr2gX2q_OdUNjXZ9yS-sQN9sWh0TSxtMh1ZjWYfox7gDYph9iU20PRCpH6sPOtfQV6Y7CNKdmjd6nQ9UG8-niJTmrse3d1e-ekOXjw3L-nC3enl7m94vMSAUZFAKVQJAoclYhoNBMi0JLx7mSaoZOotUCjba6VoUSiufAZkJYJfNcczEht8daE0PfR1eXXWw2GL9KYOVeZplklnuZCb05ot222jj7D_7ZEz-bq2_L</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Pike, Andy</creator><creator>Flanagan, Neil J</creator><creator>Storer, R Ian</creator><creator>Swain, Nigel A</creator><creator>Tseng, Elaine</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-9053-9664</orcidid></search><sort><creationdate>201809</creationdate><title>The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na v 1.7 channel blocker</title><author>Pike, Andy ; Flanagan, Neil J ; Storer, R Ian ; Swain, Nigel A ; Tseng, Elaine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561-183a63a15a370ba1a39093895e226564ae5ad93ac9d9f686362710433d6577923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Drug Interactions</topic><topic>Excipients - pharmacokinetics</topic><topic>Male</topic><topic>NAV1.7 Voltage-Gated Sodium Channel</topic><topic>Organic Anion Transporters - metabolism</topic><topic>Piperidines - pharmacokinetics</topic><topic>Polyethylene Glycols - pharmacokinetics</topic><topic>Pyridines - pharmacokinetics</topic><topic>Rats, Wistar</topic><topic>Stearic Acids - pharmacokinetics</topic><topic>Thiadiazoles - pharmacokinetics</topic><topic>Voltage-Gated Sodium Channel Blockers - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pike, Andy</creatorcontrib><creatorcontrib>Flanagan, Neil J</creatorcontrib><creatorcontrib>Storer, R Ian</creatorcontrib><creatorcontrib>Swain, Nigel A</creatorcontrib><creatorcontrib>Tseng, Elaine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Biopharmaceutics & drug disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pike, Andy</au><au>Flanagan, Neil J</au><au>Storer, R Ian</au><au>Swain, Nigel A</au><au>Tseng, Elaine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na v 1.7 channel blocker</atitle><jtitle>Biopharmaceutics & drug disposition</jtitle><addtitle>Biopharm Drug Dispos</addtitle><date>2018-09</date><risdate>2018</risdate><volume>39</volume><issue>8</issue><spage>388</spage><epage>393</epage><pages>388-393</pages><issn>0142-2782</issn><eissn>1099-081X</eissn><abstract>PF-06456384 is an extremely potent and selective blocker of the Na
1.7 sodium channel designed as a potential intravenous (i.v.) analgesic targeting high potency and rapid clearance to minimize the potential for residual effects following the end of infusion. In our previous experience targeting oral molecules, the requirement to obtain potent, Na
1.7 selective molecules led to a focus on acidic, amphipilic compounds cleared primarily by organic anion-transporting polypeptide mediated hepatic uptake and subsequent biliary excretion. However, the physicochemical properties of the i.v. lead matter were substantially different, moving from acidic, amphiphilic chemical space to zwitterions as well as substantially increasing molecular weight. This report describes the continued relevance of organic anion-transporting polypeptide driven hepatic uptake in this physicochemical space and highlights an apparent impact of the formulation excipient Solutol on the clearance and distribution of PF-06456384.</abstract><cop>England</cop><pmid>30175851</pmid><doi>10.1002/bdd.2156</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9053-9664</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0142-2782 |
ispartof | Biopharmaceutics & drug disposition, 2018-09, Vol.39 (8), p.388-393 |
issn | 0142-2782 1099-081X |
language | eng |
recordid | cdi_crossref_primary_10_1002_bdd_2156 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Animals Drug Interactions Excipients - pharmacokinetics Male NAV1.7 Voltage-Gated Sodium Channel Organic Anion Transporters - metabolism Piperidines - pharmacokinetics Polyethylene Glycols - pharmacokinetics Pyridines - pharmacokinetics Rats, Wistar Stearic Acids - pharmacokinetics Thiadiazoles - pharmacokinetics Voltage-Gated Sodium Channel Blockers - pharmacokinetics |
title | The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na v 1.7 channel blocker |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T08%3A05%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20organic%20anion-transporting%20polypeptides%20and%20formulation%20in%20the%20clearance%20and%20distribution%20of%20a%20novel%20Na%20v%201.7%20channel%20blocker&rft.jtitle=Biopharmaceutics%20&%20drug%20disposition&rft.au=Pike,%20Andy&rft.date=2018-09&rft.volume=39&rft.issue=8&rft.spage=388&rft.epage=393&rft.pages=388-393&rft.issn=0142-2782&rft.eissn=1099-081X&rft_id=info:doi/10.1002/bdd.2156&rft_dat=%3Cpubmed_cross%3E30175851%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30175851&rfr_iscdi=true |